Johnson & Johnson

JNJ · NYSE

$259.36+$5.57 (+2.19%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $253.79

JNJ analyst rating

BuyConsensus of 21 analysts over the last 12 months. 71% rate it a buy.

Strong buy0
Buy15
Hold6
Underperform0
Sell0

12-month price target · 27 analysts

Average $280.25 (+8.1% upside)

Low: $171.70
Now: $259.36
High: $336.00

Upgrades and downgrades

The latest rating actions, newest first

JNJ analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 16, 2026	Maintains	Overweight	$275.00 → $287.00	54%
Morgan Stanley	Oct 15, 2026	Maintains	Overweight	$294.00 → $292.00	63%
Leerink Partners	Oct 14, 2026	Maintains	Outperform	$276.00 → $272.00	71%
Wells Fargo	Oct 14, 2026	Maintains	Overweight	$282.00 → $275.00	54%
RBC Capital	Oct 14, 2026	Maintains	Outperform	$290.00 → $280.00	73%
Guggenheim	Oct 7, 2026	Maintains	Buy	$287.00	66%
RBC Capital	Oct 6, 2026	Maintains	Outperform	$287.00 → $290.00	73%
Citigroup	Oct 5, 2026	Maintains	Buy	$298.00 → $303.00	60%
JP Morgan	Sep 29, 2026	Maintains	Neutral	$270.00 → $285.00	65%
HSBC	Sep 10, 2026	Maintains	Buy	$290.00 → $320.00	59%

The case for and against

Updated Oct 14, 2026

Bull case

Johnson & Johnson is favored for the durability and breadth of its growth engine, with Innovative Medicine now carrying the portfolio through strong momentum in Tremfya, Darzalex, Caplyta, and newly launched assets like Icotyde and Inlexzo. The company’s pipeline and recent readouts continue to de-risk future revenue, while management’s focus on immunology, oncology, and neurology supports continued top-line expansion even as some legacy products face erosion. Its scale, leadership in multiple therapeutic franchises, and ability to generate strong cash flow after the consumer divestiture underpin confidence that it can compound earnings and reward shareholders over time.

Bear case

Johnson & Johnson is facing a cautious outlook because 3Q 2026 revenue of $25.49Bn and EPS of $2.49 are only broadly in line with consensus, while the lower EPS versus the Street likely reflects a $1.785Bn IPR&D charge tied to the Firefly and Sail deals. The 2026E outlook of $101.01Bn in sales and $11.05 in EPS sits only near the middle of guidance, suggesting limited upside as loss of exclusivity, weaker pipeline traction in products such as Inlexzo, Rybrevant and nipocalimab, and slower MedTech growth could restrain performance. Additional pressure from U.S. drug pricing reform, potential pharmaceutical tariffs, M&A integration risk, and ongoing talc and other product-liability litigation further weaken the fundamental case.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.